COMPASS Pathways plc vs Johnson & Johnson
JNJ wins the Tale of the Tape 8–1.
🏆 Tale of the Tape
Green = winner in each category. Higher is better except P/E (lower = cheaper).
Fundamentals
| Metric | CMPS | JNJ |
|---|---|---|
| Market Cap | $1.8B | $542.4B |
| P/E Ratio | — | 26.1x |
| Forward P/E | -12.4x | 17.7x |
| P/B | 5.39x | 6.68x |
| Dividend Yield | — | 2.38% |
| Beta | 2.40 | 0.26 |
Quantitative Metrics
| Metric | CMPS | JNJ |
|---|---|---|
| DCF Fair Value | — | $134.24 |
| DCF Upside | — | -43.6% |
| Piotroski F | 2/9 | 4/9 |
| Altman Z | — | 3.97 |
| Beneish M | — | -2.27 |
| FCF Yield | — | 3.25% |
| Net Debt/EBITDA | — | 0.5x |
| ROIC | — | 18.3% |
| WACC | — | 7.7% |
| ROIC – WACC | — | 10.5pp |
| Gross Margin | — | 67.9% |
| Net Margin | — | 28.5% |
| Rev Growth YoY | — | 6.0% |
| Sharpe (1Y) | — | 2.69 |
| Max Drawdown 3Y | — | -16.0% |
| FCF Payout Ratio | — | 64% |
CMPS Price
JNJ Price
ETF Exposure
JNJ found in:
More Comparisons
Quant metrics computed from financial statements and 1,200+ trading days. Correlation is Pearson coefficient on daily log returns. Not investment advice.
CMPS vs JNJ: Head-to-Head Analysis
COMPASS Pathways plc (CMPS) and Johnson & Johnson (JNJ) represent two companies in the Healthcare sector. In our quantitative Tale of the Tape scoring, JNJ leads 8–1 across nine fundamental and risk metrics including profitability, valuation, capital efficiency, and financial health.
CMPS appears in 2 ETFs tracked by SecuritiesDB, while JNJ appears in 39 ETFs. Investors holding broad-market ETFs may already have indirect exposure to both stocks.
Frequently Asked Questions
Which stock is the better investment, CMPS or JNJ?
Our quantitative analysis compares CMPS and JNJ across nine fundamental dimensions. JNJ wins the Tale of the Tape 8–1. However, stock selection depends on your individual risk tolerance, time horizon, and portfolio context. These metrics are computed from SEC filings and market data — they are not investment recommendations.
Are CMPS and JNJ correlated?
Correlation data is not yet available for this pair. Check back after both stocks have sufficient trading history.
How is the Tale of the Tape scored?
The Tale of the Tape compares both stocks across nine categories: profitability (net margin), valuation (P/E), efficiency (ROIC), health (Piotroski F-Score), safety (Altman Z-Score), growth (revenue YoY), risk (Sharpe ratio), leverage (debt-to-equity), and cash generation (FCF yield). The stock that wins more categories takes the overall score. Lower P/E and lower debt-to-equity count as wins.